20 results on '"Shaheen, Ihab"'
Search Results
2. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis
- Author
-
Ali, Hatem, Soliman, Karim M., Shaheen, Ihab, Kim, Jon Jin, Kossi, Mohsen El, Sharma, Ajay, Pararajasingam, Ravi, and Halawa, Ahmed
- Published
- 2020
- Full Text
- View/download PDF
3. Validating the use of bioimpedance spectroscopy for assessment of fluid status in children
- Author
-
Dasgupta, Indranil, Keane, David, Lindley, Elizabeth, Shaheen, Ihab, Tyerman, Kay, Schaefer, Franz, and Wühl, Elke
- Subjects
Spectroscopy -- Usage ,Children -- Health aspects ,Hemodialysis -- Usage ,Fluids -- Health aspects ,Risk assessment -- Analysis ,Health - Abstract
Background Bioimpedance spectroscopy (BIS) with a whole-body model to distinguish excess fluid from major body tissue hydration can provide objective assessment of fluid status. BIS is integrated into the Body Composition Monitor (BCM) and is validated in adults, but not children. This study aimed to (1) assess agreement between BCM-measured total body water (TBW) and a gold standard technique in healthy children, (2) compare TBW_BCM with TBW from Urea Kinetic Modelling (UKM) in haemodialysis children and (3) investigate systematic deviation from zero in measured excess fluid in healthy children across paediatric age range. Methods TBW_BCM and excess fluid was determined from standard wrist-to-ankle BCM measurement. TBW_D2O was determined from deuterium concentration decline in serial urine samples over 5 days in healthy children. UKM was used to measure body water in children receiving haemodialysis. Agreement between methods was analysed using paired t test and Bland-Altman method comparison. Results In 61 healthy children (6-14 years, 32 male), mean TBW_BCM and TBW_D2O were 21.1 ± 5.6 and 20.5 ± 5.8 L respectively. There was good agreement between TBW_BCM and TBW_D2O (R.sup.2 = 0.97). In six haemodialysis children (4-13 years, 4 male), 45 concomitant measurements over 8 months showed good TBW_BCM and TBW_UKM agreement (mean difference - 0.4 L, 2SD = ± 3.0 L). In 634 healthy children (2-17 years, 300 male), BCM-measured overhydration was - 0.1 ± 0.7 L (10-90th percentile - 0.8 to + 0.6 L). There was no correlation between age and OH (p = 0.28). Conclusions These results suggest BCM can be used in children as young as 2 years to measure normally hydrated weight and assess fluid status., Author(s): Indranil Dasgupta [sup.1] , David Keane [sup.2] , Elizabeth Lindley [sup.2] , Ihab Shaheen [sup.3] , Kay Tyerman [sup.3] , Franz Schaefer [sup.4] , Elke Wühl [sup.4] , Manfred [...]
- Published
- 2018
- Full Text
- View/download PDF
4. Tailgut cysts in children: a report of two cases and literature review
- Author
-
Haider, Nadeem, Shaheen, Ihab, Squire, Roly, and Stringer, Mark D.
- Published
- 2015
- Full Text
- View/download PDF
5. Haemofiltration therapy
- Author
-
Shaheen, Ihab, Harvey, Ben, and Watson, Alan R.
- Published
- 2009
- Full Text
- View/download PDF
6. Bilateral progressive cystic nephroma in a 9-month-old male infant requiring renal replacement therapy
- Author
-
Shaheen, Ihab Sakr, Fitzpatrick, Maggie, Brownlee, Keith, Bhuskute, Nikhil, Elliott, Martin, Powis, Mark, Ahmad, Niaz, and Tyerman, Kay
- Published
- 2010
- Full Text
- View/download PDF
7. Management of postkidney transplant anemia - is it feasible to maintain patient and allograft survival?
- Author
-
Abbas, Fedaey, El Kossi, Mohsen, Shaheen, Ihab S., Sharma, Ajay, and Halawa, Ahmed
- Published
- 2022
- Full Text
- View/download PDF
8. Update on Pediatric Hemodialysis Adequacy.
- Author
-
Moustafa, Bahia H., ElHatw, Mohamad Khaled, and Shaheen, Ihab S.
- Published
- 2022
- Full Text
- View/download PDF
9. Multicystic dysplastic kidney and pelviureteric junction obstruction
- Author
-
Shaheen, Ihab Sakr, Watson, Alan R, Broderick, Nigel, and Rance, Christopher
- Published
- 2005
- Full Text
- View/download PDF
10. CURRENT TREATMENT MODALITIES AND OUTCOMES IN CHILDREN WITH ACUTE RENAL FAILURE
- Author
-
Shaheen, Ihab Sakr, Watson, Alan R., Harvey, Ben, and Greenhalgh, Wendy
- Published
- 2003
11. Drug-Induced Myelosuppression in Kidney Transplant Patients.
- Author
-
Abbas, Fedaey, El Kossi, Mohsen, Shaheen, Ihab Sakr, Sharma, Ajay, and Halawa, Ahmed
- Published
- 2021
- Full Text
- View/download PDF
12. Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis.
- Author
-
Ali, Hatem, Mohiuddin, Atif, Sharma, Ajay, Shaheen, Ihab, Kim, Jon Jin, Kosi, Mohsen El, and Halawa, Ahmed
- Subjects
KIDNEY transplantation ,RECEPTOR antibodies ,INTERLEUKIN-2 ,RANDOM effects model ,GRAFT rejection - Abstract
Background Interleukin-2 (IL-2) antagonist has been used as an induction therapy in many centres in calcineurin inhibitor-sparing regimens. Tacrolimus has overwhelmingly replaced cyclosporine in the maintenance immunosuppressive protocols in many transplant centres. The aim of our study and meta-analysis is to explore the effect of IL-2 induction therapy on the rate of rejection and patient and graft survival in standard-risk renal transplant patients with tacrolimus-based maintenance immunotherapy. Secondary aims included assessment of the effect of IL-2 induction therapy on creatinine change and the risk of cytomegalovirus (CMV) infection. Methods We conducted a systematic review in different databases to identify studies and research work that assessed the effect of IL-2 antibody induction therapy on renal transplant outcomes. Inclusion criteria for our meta-analysis were all studies that compared IL-2 induction therapy with placebo or no induction therapy in standard-risk renal transplant recipients on tacrolimus-based maintenance immunosuppressive therapy. Data collected were the name of the first author, journal title, year of publication, country where the study was conducted, number of patients in the IL-2 induction therapy arm and in the placebo arm, number of patients who had biopsy-proven rejection and graft survival in each arm. A random effects model was used for the meta-analysis. Results Of the 470 articles found in different databases, 7 were included in the meta-analysis. Forest plot analysis for rate of rejection during the follow-up period post-transplant showed no significant difference between the groups. There was no evidence of heterogenicity between included studies (I
2 = 21.8%, P = 0.27). The overall risk difference was −0.02 [95% confidence interval (CI) −0.05–0.01]. A random effects meta-analysis for patient and graft survival was performed using forest plot analysis and showed no significant effect of IL-2 receptor (IL-2R) antibody induction on patient or graft survival compared with placebo. The overall risk difference was −0.01 (95% CI −0.04–0.01) and 0.00 (95% CI −0.00–0.01), respectively. Three of the included studies showed no effect of basiliximab on creatinine change, two showed no effect on risk of CMV infection and two showed less risk of post-transplant diabetes in the basiliximab group. Conclusion IL-2R antibody induction therapy has no significant effect on the rate of rejection or patient or graft survival in standard-risk renal transplant recipients on tacrolimus-based maintenance immunotherapy. More randomized controlled studies are needed. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Management of recurrent focal segmental glomerulosclerosis (FSGS) post renal transplantation.
- Author
-
Al Shamsi, Hefsa Rashed, Shaheen, Ihab, and Aziz, David
- Abstract
One of the common GN causing ESKD is focal segmental glomerulosclerosis (FSGS). Recurrence of FSGS post-transplantation can lead to graft loss. Data on management either prophylactically or once recurrence occurs are limited. This review article aims to assess the effective management of patients with FSGS recurrence post-transplantation, looking mainly at recurrence post prophylactic treatment and remission in case of treatment post recurrence. Twenty-three studies were included using the search MeSH terms "FSGS" "recurrence" "adults" "transplantation" "treatment". Search engines used were Pubmed, clinical key, Scopus and Cochrane library. Inclusion criteria were articles covered adult patients with recurrent FSGS post renal transplantation, treatment with rituximab and plasmapheresis, and articles published from 2000 tt2021. Excluded articles were paediatric population, studies with no reported outcomes of the treatment of FSGS, and Patients who received stem cell transplantation or galactose therapy. Prophylactic PP did not show a reduction in recurrence of FSGS in 2/3 studies. Prophylactic rituximab was shown to reduce recurrence of FSGS in one-study and case reports. Treatment of recurrent FSGS with PP showed responses ranging from 41% to 100%. Only one study did not show improvement with PP use as treatment having a 27% remission. Treatment with rituximab showed variable results, with reports showing remission ranging from 57% to 100%. Whereas other reports showing no response at all. PP prescription reporting was variable. One study suggested intensified PP regimen while in most other studies PP was guided by the response reflected by the reduction of proteinuria. Reviewing the treatment of recurrent FSGS is crucial, as there no consensus on treating FSGS as the disease is not very common in the adult population. The evidence of different modalities is based on small cohort studies. This paper supports the use of PP and RTX as treatment of recurrent FSGS. In conclusion, PP and RTX are the main modalities to treat recurrent FSGS with varying response rates. Prophylactic PP does not play a role in preventing recurrent FSGS. Prophylactic rituximab might play a role in preventing FSGS post-transplantation. PP and RTX, when used as a treatment, show variable response rates. Larger RCTs are needed to have a strong level of evidence to base our clinical management on. • Evaluate prophylactic plasmapheresis in preventing recurrent FSGS post transplantation. • Evaluate prophylactic Rituximab in preventing recurrent FSGS post transplantation. • Measure the effectiveness of plasmapheresis and rituximab in treatment of recurrence FSGS by assessing proteinuria. • Appraise other available modalities of treatment of recurrent FSGS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. The management of mineral and bone disease after kidney transplantation: A narrative overview.
- Author
-
Buttigieg, Jesmar, Bugeja, Maria, Shaheen, Ihab S., Kossi, Mohsen El, and Halawa, Ahmed
- Subjects
- *
BONE diseases , *PARATHYROIDECTOMY , *KIDNEY transplantation , *OSTEOPOROSIS , *KIDNEY diseases , *HYPERPARATHYROIDISM , *DIAGNOSTIC imaging - Abstract
Post-transplant mineral bone disease (PT-MBD) is associated with increased morbidity and mortality in kidney transplant recipients. Bone abnormalities can range from adynamic bone disease to severe persistent hyperparathyroidism with associated hypercalcemia and hypophosphataemia. In addition, these patients can develop other complications such as osteopenia and osteoporosis; further increasing the risk of fragility fractures. Appropriate management is challenging, given the lack of robust evidence. Bone turnover biomarkers and imaging studies are not entirely validated to differentiate between these pathological entities. Available interventions to control high turnover bone disease include calcimimetic drugs (Cinacalcet) and surgical parathyroidectomy. Cinacalcet has been shown to improve bone biochemistry and reduce the number of required parathyroidectomies. However, none of the meta-analyses identified a significant reduction in the overall mortality. Cinacalcet remains the treatment of choice for high turnover bone disease in the first year after transplantation, sometimes serving as a precursor to the surgery. In general, severe hyperparathyroidism does not respond adequately to cinacalcet alone, and many of these patients would eventually require parathyroidectomy. In our opinion, total parathyroidectomy should be avoided as this leads to undetectable PTH and subsequent adynamic bone disease. Anti-resorptive treatment, on the other hand, is indicated for proven osteoporosis if excretory graft function permits. In this narrative review, we provide an overview of the management of PT-MBD, based on the current best available evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Journey of a patient with scleroderma from renal failure up to kidney transplantation.
- Author
-
Abbas F, El Kossi M, Shaheen IS, Sharma A, and Halawa A
- Abstract
The increased awareness of systemic sclerosis (SS) and its pathogenetic background made the management of this disease more amenable than previously thought. However, scleroderma renal crisis (SRC) is a rarely seen as an associated disorder that may involve 2%-15% of SS patients. Patients presented with earlier, rapidly progressing, diffuse cutaneous SS disease, mostly in the first 3-5 years after non-Raynaud clinical manifestations, are more vulnerable to develop SRC. SRC comprises a collection of acute, mostly symptomatic rise in blood pressure, elevation in serum creatinine concentrations, oliguria and thrombotic microangiopathy in almost 50% of cases. The advent of the antihypertensive angiotensin converting enzyme inhibitors in 1980 was associated with significant improvement in SRC prognosis. In a scleroderma patient maintained on regular dialysis; every effort should be exerted to declare any possible evidence of renal recovery. A given period of almost two years has been suggested prior to proceeding in a kidney transplant (KTx). Of note, SS patients on dialysis have the highest opportunity of renal recovery and withdrawal from dialysis as compared to other causes of end-stage renal disease (ESRD). KTx that is the best well-known therapeutic option for ESRD patients can also be offered to SS patients. Compared to other primary renal diseases, SS-related ESRD was considered for a long period of poor patient and allograft survivals. Pulmonary involvement in an SS patient is considered a strong post-transplant independent risk factor of death. Recurrence of SRC after transplantation has been observed in some patients. However, an excellent post-transplant patient and graft outcome have been recently reported. Consequently, the absence of extrarenal manifestations in an SS-induced ESRD patient can be accepted as a robust indicator for a successful KTx., Competing Interests: Conflict-of-interest statement: Fedaey Abbas is an employee (under contract) of MOD, Kuwait., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.
- Author
-
Abbas F, El Kossi M, Shaheen IS, Sharma A, and Halawa A
- Abstract
Transplant recipients are vulnerable to a higher risk of malignancy after solid organ transplantation and allogeneic hematopoietic stem-cell transplant. Post-transplant lymphoproliferative disorders (PTLD) include a wide spectrum of diseases ranging from benign proliferation of lymphoid tissues to frank malignancy with aggressive behavior. Two main risk factors of PTLD are: Firstly, the cumulative immunosuppressive burden, and secondly, the oncogenic impact of the Epstein-Barr virus. The latter is a key pathognomonic driver of PTLD evolution. Over the last two decades, a considerable progress has been made in diagnosis and therapy of PTLD. The treatment of PTLD includes reduction of immunosuppression, rituximab therapy, either isolated or in combination with other chemotherapeutic agents, adoptive therapy, surgical intervention, antiviral therapy and radiotherapy. In this review we shall discuss the prevalence, clinical clues, prophylactic measures as well as the current and future therapeutic strategies of this devastating disorder., Competing Interests: Conflict-of-interest statement: No conflict of interest., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases.
- Author
-
Abbas F, El Kossi M, Kim JJ, Shaheen IS, Sharma A, and Halawa A
- Abstract
For decades, kidney diseases related to inappropriate complement activity, such as atypical hemolytic uremic syndrome and C3 glomerulopathy (a subtype of membranoproliferative glomerulonephritis), have mostly been complicated by worsened prognoses and rapid progression to end-stage renal failure. Alternative complement pathway dysregulation, whether congenital or acquired, is well-recognized as the main driver of the disease process in these patients. The list of triggers include: surgery, infection, immunologic factors, pregnancy and medications. The advent of complement activation blockade, however, revolutionized the clinical course and outcome of these diseases, rendering transplantation a viable option for patients who were previously considered as non-transplantable cases. Several less-costly therapeutic lines and likely better efficacy and safety profiles are currently underway. In view of the challenging nature of diagnosing these diseases and the long-term cost implications, a multidisciplinary approach including the nephrologist, renal pathologist and the genetic laboratory is required to help improve overall care of these patients and draw the optimum therapeutic plan., Competing Interests: Conflict-of-interest statement: No conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
18. Focal segmental glomerulosclerosis in a female patient with Donnai-Barrow syndrome.
- Author
-
Shaheen IS, Finlay E, Prescott K, Russell M, Longoni M, and Joss S
- Subjects
- Agenesis of Corpus Callosum, Child, Craniofacial Abnormalities genetics, Eye Abnormalities genetics, Female, Glomerulosclerosis, Focal Segmental genetics, Hearing Loss genetics, Hernia diagnosis, Humans, Karyotyping, Phenotype, Proteinuria diagnosis, Proteinuria genetics, Syndrome, Craniofacial Abnormalities diagnosis, Eye Abnormalities diagnosis, Glomerulosclerosis, Focal Segmental diagnosis, Hearing Loss diagnosis, Low Density Lipoprotein Receptor-Related Protein-2 genetics
- Published
- 2010
- Full Text
- View/download PDF
19. Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children.
- Author
-
Shaheen IS, Harvey B, Watson AR, Pandya HC, Mayer A, and Thomas D
- Subjects
- Adolescent, Child, Child, Preschool, Demography, Female, Hospital Mortality, Humans, Infant, Infant, Newborn, Intensive Care Units, Pediatric, Male, Prospective Studies, Treatment Outcome, Extracorporeal Membrane Oxygenation, Hemofiltration methods, Kidney Diseases therapy
- Abstract
Objectives: We report the frequency of usage, patient demographics, and outcomes in children treated with continuous venovenous hemofiltration (CVVH) in three pediatric intensive care units (PICUs), with one unit providing combined extracorporeal membrane oxygenation (ECMO) and CVVH., Design: Prospective database analysis., Setting: Three regional PICUs in the Trent Haemofiltration Network with two general PICUs admitting 450-500 patients annually and the other providing regional cardiac support and a supraregional service for ECMO (600-650 admissions annually with 50 ECMO patients)., Patients: Children who underwent CVVH alone or in combination with ECMO or other therapies between January 2000 and December 2002., Interventions: None., Measurements and Main Results: There were 115 children (58 male) treated, with a median age of 18 months (range 1 day to 17 yrs) and median weight of 12 kg (range 1.8-119 kg). In the two PICUs without ECMO, CVVH was undertaken in 2.5% of admissions annually compared with 3% of annual admissions to the PICU with an ECMO service. Fifty-five patients received CVVH alone (group 1), while 53 patients underwent CVVH in conjunction with ECMO (group 2). In addition, five patients received plasmafiltration followed by CVVH, and two patients were treated with combined CVVH and molecular adsorbents recirculating system. Mean duration of therapy in group 1 was 142 hrs (1-840 hrs) and in group 2,231 hrs (3-1104 hrs). Overall patient survival was 43% with 29 of 55 (53%) CVVH patients surviving and 18 of 53 (34%) of those treated with ECMO plus CVVH., Conclusions: Performing CVVH in a heterogeneous population with large age and weight ranges poses significant clinical and technical challenges. The low frequency of CVVH use, as well as the use of other extracorporeal therapies, also raises problems with maintaining nursing skills. Objective clinical and biochemical markers for commencing CVVH alone or in combination with ECMO remain to be defined.
- Published
- 2007
- Full Text
- View/download PDF
20. Acute renal failure in children: etiology, treatment and outcome.
- Author
-
Shaheen IS, Watson AR, and Harvey B
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Combined Modality Therapy, England epidemiology, Female, Hemofiltration, Humans, Infant, Infant, Newborn, Intensive Care Units, Pediatric, Male, Peritoneal Dialysis, Prospective Studies, Renal Dialysis, Renal Replacement Therapy, Treatment Outcome, Acute Kidney Injury etiology, Acute Kidney Injury mortality, Acute Kidney Injury therapy
- Abstract
Children with acute renal failure (ARF) may be treated in pediatric renal or intensive care (PICU) units where there is an increasing use of continuous renal replacement therapies such as hemofiltration (HF). Over three years, we prospectively recorded details of all patients with ARF treated both within our regional pediatric renal unit, in two local neonatal intensive care units (NICUs), and one PICU, which are all supported by our institution. Our study included eighty-three ARF patients (43% male) with a median age of 5.7 years (range 1 day - 19.8 years); 41% of patients were < 2 years, 20% 2-5 years, 13% 5-10 years and 26% > 10 years of age. A total of 37 patients (45%) were treated in the renal unit versus 46 (55%) patients in NICU/PICU. The initial treatment modality was conservative in 33%, peritoneal dialysis (PD) in 23%, hemodialysis (HD) in 15%, HF in 28%, and isolated plasmafiltration in one percent of the patients. About 16% of the patients required more than one treatment modality. Outcome data at three months showed normal renal function in 49%, deaths in 20%, dialysis dependent disease in 14%, chronic renal failure (GFR < 60ml/min/1.73m2) in eight percent, and proteinuria and/or hypertension in seven percent of the patients. Only one (3%) death occurred in 37 patients treated in the renal unit compared to 16 deaths in 46 patients (35%) treated in the NICU/PICU. Our findings further confirm the low mortality rate with isolated renal failure and the substantial mortality and renal workload in intensive care areas where renal failure is often part of multi-organ failure. Further prospective studies will be required to analyze the impact of early hemofiltration in such patients.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.